Solid Biosciences Inc.2024财年实现净利润-1.25亿美元，同比减少30.18%

市场透视2025-03-10

3月10日，Solid Biosciences Inc.（SLDB.US）公布财报，公告显示公司2024财年净利润为-1.25亿美元，同比减少30.18%；其中营业收入为0.00美元，每股基本收益为-3.06美元。从资产负债表来看，Solid Biosciences Inc.（SLDB.US）总负债51.42百万美元，其中短期债务3.02百万美元，资产负债比为0.04，流动比率为0.06。机构评级...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2518281162?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-10 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2518281162","market":"us","top_or_hot":-1,"title":"Solid Biosciences Inc.2024财年实现净利润-1.25亿美元，同比减少30.18%","media":"市场透视","content":"<div>\n<p>3月10日，Solid Biosciences Inc.（SLDB.US）公布财报，公告显示公司2024财年净利润为-1.25亿美元，同比减少30.18%；其中营业收入为0.00美元，每股基本收益为-3.06美元。从资产负债表来看，Solid Biosciences Inc.（SLDB.US）总负债51.42百万美元，其中短期债务3.02百万美元，资产负债比为0.04，流动比率为0.06。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000312abf17590&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solid Biosciences Inc.2024财年实现净利润-1.25亿美元，同比减少30.18%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolid Biosciences Inc.2024财年实现净利润-1.25亿美元，同比减少30.18%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-10 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000312abf17590&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月10日，Solid Biosciences Inc.（SLDB.US）公布财报，公告显示公司2024财年净利润为-1.25亿美元，同比减少30.18%；其中营业收入为0.00美元，每股基本收益为-3.06美元。从资产负债表来看，Solid Biosciences Inc.（SLDB.US）总负债51.42百万美元，其中短期债务3.02百万美元，资产负债比为0.04，流动比率为0.06。机构评级...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000312abf17590&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLDB","symbol_name":"Solid Biosciences","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000312abf17590&s=b","article_id":"2518281162","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000312abf17590&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2518281162","pubTimestamp":1741536087,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月10日，Solid Biosciences Inc.公布财报，公告显示公司2024财年净利润为-1.25亿美元，同比减少30.18%；其中营业收入为0.00美元，每股基本收益为-3.06美元。从资产负债表来看，Solid Biosciences Inc.总负债51.42百万美元，其中短期债务3.02百万美元，资产负债比为0.04，流动比率为0.06。机构评级：截至2025年3月10日，当前有9家机构对Solid Biosciences Inc.目标价做出预测，其中目标均价为16.89美元，其中最低目标价为15.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"SLDB":"Solid Biosciences"},"translate_title":"Solid Biosciences Inc. achieved net profit of-$125 million in fiscal 2024, a year-on-year decrease of 30.18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":1},"content_text":"3月10日，Solid Biosciences Inc.（SLDB.US）公布财报，公告显示公司2024财年净利润为-1.25亿美元，同比减少30.18%；其中营业收入为0.00美元，每股基本收益为-3.06美元。从资产负债表来看，Solid Biosciences Inc.（SLDB.US）总负债51.42百万美元，其中短期债务3.02百万美元，资产负债比为0.04，流动比率为0.06。机构评级：截至2025年3月10日，当前有9家机构对Solid Biosciences Inc.目标价做出预测，其中目标均价为16.89美元，其中最低目标价为15.00美元，最高目标价为20.00美元。公司简介：Solid Biosciences Inc 是一家生命科学公司。 该公司从事特种药品和仿制药的生产。 该公司致力于治疗杜氏肌营养不良症 (DMD)，这是一种主要影响男孩的遗传性肌肉萎缩疾病，其症状通常在三到五岁之间出现。 该公司的药物管线有SB-001和固体套装。 该公司的单一重点是通过基因疗法和其他手段为神经肌肉和心脏病患者开发治疗方法。 该公司将其项目分为矫正疗法、疾病修饰疗法和辅助设备。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518281162","isCrawlerRequest":true}